Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan has head start on US Adcirca rival

Executive Summary

Mylan has strengthened the firm’s cardiovascular portfolio in the US by launching the first generic of Eli Lilly’s Adcirca (tadalafil) 20mg tablets with 180 days of marketing exclusivity. The launch comes shortly after Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) referencing the treatment for pulmonary arterial hypertension to improve exercise ability.

You may also be interested in...

Mylan Reforms As It Prepares To Become Viatris

Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.

Tadalafil Launches In US Follow Teva's 180-Day Expiry

Multiple generic versions of Eli Lilly’s Cialis (tadalafil) tablets have been launched in the US, following the expiry of Teva’s 180-day exclusivity. The Israeli company introduced its first-to-file version of its Cialis rival in September 2018; now a number of firms have obtained approval, while others have launched generic alternatives.

Teva Introduces First Sabril Rival In US

Teva has introduced the first generic version of Lundbeck’s Sabril 500mg tablets in the US, less than a month after obtaining FDA approval for the drug.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts